Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Ultrafast rotation of magnetically levitated macroscopic steel spheres.

Schuck M, Steinert D, Nussbaumer T, Kolar JW.

Sci Adv. 2018 Jan 5;4(1):e1701519. doi: 10.1126/sciadv.1701519. eCollection 2018 Jan.

2.

[This far it can go without HIV therapy!].

Bogner JR, Steinert D, Coppenrath E.

MMW Fortschr Med. 2016 Jun 9;158 Suppl 1:7. doi: 10.1007/s15006-016-8308-8. German. No abstract available.

PMID:
27259886
3.

EGF receptor signaling is involved in expression of osmoprotective TonEBP target gene aldose reductase under hypertonic conditions.

Küper C, Steinert D, Fraek ML, Beck FX, Neuhofer W.

Am J Physiol Renal Physiol. 2009 May;296(5):F1100-8. doi: 10.1152/ajprenal.90402.2008. Epub 2009 Feb 18.

4.

PGE2 potentiates tonicity-induced COX-2 expression in renal medullary cells in a positive feedback loop involving EP2-cAMP-PKA signaling.

Steinert D, Küper C, Bartels H, Beck FX, Neuhofer W.

Am J Physiol Cell Physiol. 2009 Jan;296(1):C75-87. doi: 10.1152/ajpcell.00024.2008. Epub 2008 Nov 12.

5.

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.

McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6727-34.

6.

Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients.

Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, El-Naggar AK, Benjamin RS, Zhang W, Trent JC.

Cancer. 2007 Nov 15;110(10):2293-303.

7.

Prostaglandin E2 stimulates expression of osmoprotective genes in MDCK cells and promotes survival under hypertonic conditions.

Neuhofer W, Steinert D, Fraek ML, Beck FX.

J Physiol. 2007 Aug 15;583(Pt 1):287-97. Epub 2007 Jun 7.

8.

Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.

Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK.

Cancer. 2006 Nov 1;107(9):2237-44.

9.

Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.

Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC.

Cancer. 2006 Apr 1;106(7):1617-23.

10.

Recent studies in novel therapy for metastatic sarcomas.

Steinert DM, Patel SR.

Hematol Oncol Clin North Am. 2005 Jun;19(3):573-90, viii. Review.

PMID:
15939198
11.

Imatinib mesylate in the treatment of gastrointestinal stromal tumour.

Steinert DM, McAuliffe JC, Trent JC.

Expert Opin Pharmacother. 2005 Jan;6(1):105-13. Review.

PMID:
15709888
12.

Update on the biology and therapy of gastrointestinal stromal tumors.

D'Amato G, Steinert DM, McAuliffe JC, Trent JC.

Cancer Control. 2005 Jan-Feb;12(1):44-56. Review.

PMID:
15668652
13.

Molecular targets in therapy for human soft-tissue and bone sarcomas.

Steinert DM, Blakely LJ, Salganick J, Trent JC.

Curr Oncol Rep. 2003 Jul;5(4):295-303. Review.

PMID:
12781071
14.

Successful combination endoscopic therapy for duodenal Dieulafoy's lesion.

Steinert D, Masand-Rai A.

Am J Gastroenterol. 1996 Apr;91(4):818-9. No abstract available.

PMID:
8677968

Supplemental Content

Loading ...
Support Center